AR071741A1 - Vacunas contra la malaria - Google Patents
Vacunas contra la malariaInfo
- Publication number
- AR071741A1 AR071741A1 ARP080105601A ARP080105601A AR071741A1 AR 071741 A1 AR071741 A1 AR 071741A1 AR P080105601 A ARP080105601 A AR P080105601A AR P080105601 A ARP080105601 A AR P080105601A AR 071741 A1 AR071741 A1 AR 071741A1
- Authority
- AR
- Argentina
- Prior art keywords
- component
- formulation
- antigen
- stabilizing agent
- mpl
- Prior art date
Links
- 201000004792 malaria Diseases 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 6
- 238000009472 formulation Methods 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- 239000003381 stabilizer Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 229940124735 malaria vaccine Drugs 0.000 abstract 2
- 108010024636 Glutathione Proteins 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
- 240000009188 Phyllostachys vivax Species 0.000 abstract 1
- 101710137302 Surface antigen S Proteins 0.000 abstract 1
- 229960004308 acetylcysteine Drugs 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 abstract 1
- 229940046307 sodium thioglycolate Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 150000003573 thiols Chemical group 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere a un componente para una vacuna contra la malaria que comprende: a) una part¡cula inmunogena RTS,S y/o b) una part¡cula inmunogena que se deriva de la prote¡na CS de una o m s cepas de P. vivax y el ant¡geno S de la Hepatitis B y opcionalmente el ant¡geno S sin fusionar, o, c) una part¡cula inmunogena que comprende RTS, CSV-S y opcionalmente el ant¡geno S sin fusionar, y d) un agente estabilizante que comprende un agente estabilizante con al menos un grupo funcional tiol, o sus mezclas. Tambien se describen procedimientos para preparar el componente, su uso en medicina, en particular en la prevencion de infecciones de malaria, composiciones/vacunas que contienen el componente y su uso, en particular en terapia. Reivindicacion 2: Un componente tal como se reivindica en la reivindicacion 1, en el que el agente estabilizante es N-acetil ciste¡na, monotioglicerol, ciste¡na, glutationa reducida y tioglicolato sodico o sus mezclas. Reivindicacion 4: Un componente de acuerdo con cualquiera de las reivindicaciones 1 a 3, en el que el componente es una formulacion l¡quida, Reivindicacion 6: Un componente de acuerdo con cualquiera de las reivindicaciones 1 a 3, en el que la formulacion est liofilizada. Reivindicacion 25: Una vacuna contra la malaria que comprende un componente tal como se define en una cualquiera de las reivindicaciones 1 a 23 y un adyuvante que se selecciona a partir de: a) una formulacion de aceite en agua que comprende QS21 y 3D-MPL, o b) una formulacion en liposomas que comprende QS21 y 3D-MPL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1576207P | 2007-12-21 | 2007-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071741A1 true AR071741A1 (es) | 2010-07-14 |
Family
ID=40584700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105601A AR071741A1 (es) | 2007-12-21 | 2008-12-19 | Vacunas contra la malaria |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100272745A1 (es) |
| EP (1) | EP2234637A2 (es) |
| JP (1) | JP2011507816A (es) |
| KR (1) | KR20100109556A (es) |
| CN (1) | CN102026657A (es) |
| AP (1) | AP2010005296A0 (es) |
| AR (1) | AR071741A1 (es) |
| AU (1) | AU2008339980A1 (es) |
| BR (1) | BRPI0822098A2 (es) |
| CA (1) | CA2708716A1 (es) |
| CL (1) | CL2008003808A1 (es) |
| CO (1) | CO6300963A2 (es) |
| CR (1) | CR11577A (es) |
| DO (1) | DOP2010000189A (es) |
| IL (1) | IL206308A0 (es) |
| MA (1) | MA32030B1 (es) |
| MX (1) | MX2010006984A (es) |
| PE (1) | PE20091528A1 (es) |
| TW (1) | TW200940086A (es) |
| UY (1) | UY31569A1 (es) |
| WO (1) | WO2009080715A2 (es) |
| ZA (1) | ZA201004304B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013142278A1 (en) * | 2012-03-22 | 2013-09-26 | New York University | Plasmodium vivax vaccine compositions |
| WO2016184784A1 (en) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1 |
| CN108778289B (zh) | 2015-11-06 | 2020-11-17 | 佐剂技术公司 | 三萜皂苷类似物 |
| CN105233296B (zh) * | 2015-11-24 | 2018-08-17 | 江苏省农业科学院 | 用于鸭病毒性肝炎活疫苗的耐热冻干保护剂及其制备方法和应用 |
| GB201608821D0 (en) | 2016-05-19 | 2016-07-06 | Isis Innovation | Vaccines |
| JP7177082B2 (ja) * | 2017-04-25 | 2022-11-22 | アジュバンス・テクノロジーズ・インコーポレーテッド | トリテルペンサポニン類似物 |
| AU2018258070A1 (en) * | 2017-04-25 | 2019-10-24 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
| KR20200098476A (ko) | 2017-10-16 | 2020-08-20 | 아쥬반스 테크놀로지스 인코포레이티드 | 트리테르펜 사포닌 유사체 |
| JP2022526334A (ja) | 2019-03-25 | 2022-05-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 新たなタウ種を標的化することによるタウオパチー障害の処置の方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8819209D0 (en) * | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
| CA2075521C (en) * | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
| ES2234018T3 (es) * | 1996-04-26 | 2005-06-16 | MERCK & CO., INC. | Formulaciones de vacunas de adn. |
| ZA973642B (en) * | 1996-04-26 | 1997-11-25 | Merck & Co Inc | DNA vaccine formulations. |
| GB9616351D0 (en) * | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
| EP1009382B1 (en) * | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| WO2000072872A1 (en) * | 1999-06-02 | 2000-12-07 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| KR100785601B1 (ko) * | 2003-11-21 | 2007-12-14 | 화이자 프로덕츠 인크. | 백신 아쥬반트로서의 항생제의 용도 |
| KR101365375B1 (ko) * | 2004-02-02 | 2014-02-19 | 타녹스 인코퍼레이티드 | 신규한 ＩｇＥ 에피토프의 확인 |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| BRPI0620693A2 (pt) * | 2005-12-15 | 2016-12-13 | Aeras Global Tb Vaccine Found | método para suscitar uma resposta imune tanto sistêmica como de mucosa a mycobacteria viva atenuada ou antígenos micobacterianos em um hospedeiro |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
-
2008
- 2008-12-18 KR KR1020107016404A patent/KR20100109556A/ko not_active Withdrawn
- 2008-12-18 BR BRPI0822098-0A patent/BRPI0822098A2/pt not_active IP Right Cessation
- 2008-12-18 CL CL2008003808A patent/CL2008003808A1/es unknown
- 2008-12-18 EP EP08864235A patent/EP2234637A2/en not_active Withdrawn
- 2008-12-18 MX MX2010006984A patent/MX2010006984A/es not_active Application Discontinuation
- 2008-12-18 CN CN2008801272415A patent/CN102026657A/zh active Pending
- 2008-12-18 WO PCT/EP2008/067925 patent/WO2009080715A2/en not_active Ceased
- 2008-12-18 US US12/809,727 patent/US20100272745A1/en not_active Abandoned
- 2008-12-18 AP AP2010005296A patent/AP2010005296A0/en unknown
- 2008-12-18 AU AU2008339980A patent/AU2008339980A1/en not_active Abandoned
- 2008-12-18 CA CA2708716A patent/CA2708716A1/en not_active Abandoned
- 2008-12-18 JP JP2010538733A patent/JP2011507816A/ja active Pending
- 2008-12-19 PE PE2008002169A patent/PE20091528A1/es not_active Application Discontinuation
- 2008-12-19 TW TW097149849A patent/TW200940086A/zh unknown
- 2008-12-19 UY UY31569A patent/UY31569A1/es unknown
- 2008-12-19 AR ARP080105601A patent/AR071741A1/es not_active Application Discontinuation
-
2010
- 2010-06-10 IL IL206308A patent/IL206308A0/en unknown
- 2010-06-11 CO CO10071045A patent/CO6300963A2/es not_active Application Discontinuation
- 2010-06-17 ZA ZA2010/04304A patent/ZA201004304B/en unknown
- 2010-06-18 DO DO2010000189A patent/DOP2010000189A/es unknown
- 2010-07-19 MA MA33035A patent/MA32030B1/fr unknown
- 2010-07-21 CR CR11577A patent/CR11577A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102026657A (zh) | 2011-04-20 |
| US20100272745A1 (en) | 2010-10-28 |
| MX2010006984A (es) | 2010-10-25 |
| ZA201004304B (en) | 2012-11-28 |
| TW200940086A (en) | 2009-10-01 |
| KR20100109556A (ko) | 2010-10-08 |
| UY31569A1 (es) | 2009-08-03 |
| CO6300963A2 (es) | 2011-07-21 |
| AP2010005296A0 (en) | 2010-06-30 |
| WO2009080715A3 (en) | 2009-11-12 |
| AU2008339980A1 (en) | 2009-07-02 |
| MA32030B1 (fr) | 2011-01-03 |
| BRPI0822098A2 (pt) | 2015-06-30 |
| EP2234637A2 (en) | 2010-10-06 |
| PE20091528A1 (es) | 2009-10-29 |
| CL2008003808A1 (es) | 2011-03-11 |
| CA2708716A1 (en) | 2009-07-02 |
| DOP2010000189A (es) | 2010-08-15 |
| CR11577A (es) | 2010-09-03 |
| WO2009080715A2 (en) | 2009-07-02 |
| JP2011507816A (ja) | 2011-03-10 |
| IL206308A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071741A1 (es) | Vacunas contra la malaria | |
| MX2010008468A (es) | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. | |
| AR078885A2 (es) | Composiciones estabilizadas de proteinas que tienen un radical tiol libre. recipiente impermeable. metodo. | |
| BR0315767A (pt) | Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador | |
| PE20120319A1 (es) | Composiciones adyuvantes que comprenden un agente de isotonicidad no ionico | |
| DE60121136D1 (de) | Proteasom-influenzavirus-impfstoffzusammensetzung | |
| AR073452A1 (es) | Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis | |
| BRPI0715396B8 (pt) | método de produção de uma composição para vacina | |
| AR071917A1 (es) | Vacunas contra la coccidiosis | |
| CL2011003192A1 (es) | Acido (2s)-3-(2-fluoro-5-(5-fluoro-1h-pirrolo[2,3-b]piridin-3-il)fenilamino)biciclo[2.2.2]octano-2-carboxilico; metodo para prepararlo; composicion farmaceutica que lo comprende; y su uso en el tratamiento de la influenza; metodo para reducir el virus de la influenza in vitro. | |
| WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
| BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
| BR112015001313A2 (pt) | composições de vacina | |
| CO6150189A2 (es) | Vacunas para malaria | |
| MX2019005137A (es) | Vacuna contra parvovirus porcino. | |
| MX378901B (es) | Formulaciones liquidas estables de virus de vacuna. | |
| BRPI0707779B8 (pt) | antígeno isolado, composição de vacina e método para produção de uma proteína antígeno | |
| CO6321162A2 (es) | Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante | |
| AR067087A1 (es) | Composicion de vacuna y metodo para elaborarla | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| ES2195169T3 (es) | Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion. | |
| BR112014017242A2 (pt) | vlps contendo hpv l2 imunogênico e composições e métodos relacionados | |
| BR112012030619A2 (pt) | concentração de antígenos de vacina influenza sem liofilização. | |
| MX2017003117A (es) | Particula tipo virus de flavivirus. | |
| WO2013104995A3 (en) | Compositions and methods for treating viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |